ERT Pharmacology Model for TfR-Mediated Brain Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current enzyme replacement therapies (ERT) for lysosomal storage disorders, such as Hunter syndrome, face challenges in effectively delivering recombinant enzymes across the blood-brain barrier, leading to negligible brain exposure and insufficient treatment of neurocognitive deterioration.
Innovation Solution
A method is provided for modeling the pharmacokinetics and pharmacodynamics of ERT using a model with compartments representing different tissue types, including a TfR-binding moiety, to predict and estimate enzyme concentrations and effects in tissues like the brain, utilizing equations to determine input and output rates based on binding affinity and valency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If systemic ERT with IDS is administered, then GAG reduction is achieved in peripheral tissues, but brain exposure is negligible due to BBB permeability issues
Solution Approach 1:
The patent introduces a TfR-binding moiety as an intermediary that mediates the transport of recombinant IDS across the blood-brain barrier. This moiety binds to transferrin receptors on the BBB, enabling receptor-mediated transcytosis that overcomes the permeability barrier and delivers the enzyme into the brain parenchyma.
Solution Approach 2:
The patent modifies the pharmacokinetic parameters of the therapeutic agent by incorporating a TfR-binding moiety, which changes the binding affinity and transport characteristics. This parameter change enables the enzyme to cross the BBB while maintaining its catalytic activity, thereby increasing brain exposure without compromising peripheral efficacy.
2Quantity of substance
If intrathecal IDS administration is used, then CSF GAG reduction is achieved, but cognitive improvement is insufficient despite reduced cerebrospinal fluid GAGs
Solution Approach 1:
The patent segments the brain into different compartments (superficial brain, deep brain, CSF) and models the transport of IDS into each compartment separately. This segmentation allows for optimized dosing strategies that ensure sufficient enzyme delivery to both CSF and brain parenchyma, addressing the limitation of intrathecal administration that only reduces CSF GAGs without adequately treating deep brain pathology.
3Quantity of substance
If recombinant enzyme is delivered across the BBB, then brain exposure is improved, but delivery efficiency remains insufficient for treating neurocognitive deterioration
Solution Approach 1:
The TfR-binding moiety serves as a mediator that significantly enhances delivery efficiency by utilizing the transferrin receptor pathway. This intermediary mechanism increases the rate and amount of enzyme delivery across the BBB compared to passive diffusion or intrathecal administration, making it effective for treating neurocognitive deterioration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate prediction of enzyme concentrations and therapeutic effects in brain tissues, allowing for optimized dosing and improved treatment of CNS-associated symptoms.
Implementation Method 1
the input rate and the output rate of the therapeutic agent depend on the binding affinity of the TfR-binding moiety to TfR
Data Source
AI summary
This disclosure relates to systems and methods for modeling the pharmacokinetics and pharmacodynamics of enzyme replacement therapies (ERT) in various systems and tissues.